RNFL loss tied to slower reaction times

Article

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Researchers at the Hamilton Glaucoma Center, University of California San Diego, USA, conducted a cross-sectional observational study of 158 subjects from the Diagnostic Innovations in Glaucoma Study: 82 subjects with glaucoma and 76 controls of similar age.

The researchers measured the subjects’ reaction times to peripheral stimuli at low, medium, or high contrast while the subjects performed simulated driving tasks such as negotiating a curve or following another car.

They discovered that the glaucoma subjects' mean reaction times to the low contrast stimulus were 1.19 seconds for car following and 1.05 seconds for curve negotiation. The control subjects’ reaction times were 0.77 seconds and 0.64 seconds, respectively, for the two tasks.

A non-linear relationship was found between reaction times and the retinal nerve fibre layer thickness (RNFL) in the subjects’ better eye. After the researchers adjusted for factors such as age, cognitive ability and standard automated perimetry deviation in the better eye, RNFL thickness still remained significantly associated with reaction times.

"Information from structural tests may improve our ability to determine which patients are likely to have problems performing daily activities, such as driving," the researchers concluded.

To read an abstract of the study visit the American Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.